

AHA/ASA GUIDELINE

2023 Guideline for the Management of Patients With Aneurysmal Subarachnoid Hemorrhage: A Guideline From the American Heart Association/American Stroke Association

The American Academy of Neurology affirms the value of this statement as an educational tool for neurologists.

The American Association of Neurological Surgeons/Congress of Neurological Surgeons Cerebrovascular Section affirms the educational benefit of this document.

Endorsed by the Neurocritical Care Society, Society of Neurointerventional Surgery, and Society of Vascular and Interventional Neurology

Brian L. Hoh, MD, MBA, FAHA, Chair; Nerissa U. Ko, MD, MAS, Vice Chair; Sepideh Amin-Hanjani, MD, FAHA*; Sherry Hsiang-Yi Chou, MD, MSc†; Salvador Cruz-Flores, MD, MPH, FAHA‡; Neha S. Dangayach, MD, MBBS, MSCR; Colin P. Derdeyn, MD, FAHA; Rose Du, MD, PhD; Daniel Hänggi, MD, PhD; Steven W. Hetts, MD§; Nneka L. Ifejika, MD, MPH, FAHA; Regina Johnson, BS; Kiffon M. Keigher, DNP, MSN, ACNP-BC, RN; Thabele M. Leslie-Mazwi, MD ; Brandon to provide patient-centric recommendations for the management of acute subarachnoid hemorrhage.

METHODS: A comprehensive search for literature involving human subjects, published in English

TABLE OF CONTENTS

Abstract

invasive monitoring may also be useful in patients with high-grade aSAH with limited neurological examination.

7. Early initiation of enteral nimodipine is beneficial in preventing delayed cerebral ischemia and improving functional outcomes after aSAH. Routine use of statin therapy and intravenous magnesium is not recommended.
8. Elevating blood pressure and maintaining euvolemia in patients with symptomatic delayed cerebral ischemia can be beneficial in reducing the progression and severity of delayed cerebral ischemia. However, prophylactic hemodynamic augmentation and hypervolemia should not be performed to minimize iatrogenic patient risks.
9. Cerebrovascular imaging after treatment and subsequent imaging monitoring are important in treatment planning for remnants, recurrence, or regrowth of the treated aneurysm and to identify changes in other known aneurysms. Although the risk of rerupture is low, the use of imaging to guide treatment decisions that may reduce the risk of future aSAH among survivors is recommended, especially in patients with residual aneurysm. Imaging monitoring for the development of de novo aneurysms is also important in younger patients with multiple aneurysms or with ≥ 2 first-degree relatives with aSAH.
10. A multidisciplinary team approach to identify discharge needs and design rehabilitation treatment is recommended. Among aSAH survivors, physical, cognitive, behavioral, and quality of life deficits are common and can persist. Early identification with validated screening tools can identify deficits, especially in behavioral and cognitive domains. Interventions for mood disorders can improve long-term outcomes, and counseling on the higher risk for long-term cognitive dysfunction may be beneficial.

PREAMBLE

Since 1990, the American Heart Association has published clinical practice guidelines for the management of patients with aSAH.

Surgeons, American Academy of Neurology, Neurocritical Care Society, Society of Neurointerventional Surgery, Society of Vascular and Interventional Neurology, and 39 individual content reviewers. Appendix 2 lists the reviewers' comprehensive disclosure information.

1.4. Scope of the Guideline

This guideline addresses the diagnosis and treatment of aSAH in adults and is intended to update and replace the AHA/ASA 2012 aSAH guideline.¹² This 2023 guideline is limited explicitly to aSAH and does not address other types of SAH such as those caused by trauma, vascular malformation, or hemorrhage-prone neoplasm. Furthermore, this guideline does not overlap with AHA/ASA guidelines or scientific statements on the treatment of intracerebral hemorrhage (ICH),¹³ arteriovenous malformations,¹⁴ and unruptured intracranial aneurysms.¹⁵

This guideline aims to cover the full course of aSAH (Figure 1), from initial diagnosis (Section 4), systems of

care (Section 5), and acute interventions (Sections 6, 7, and 7.1) to further inpatient care of post-aSAH complications (Sections 8–8.5). New sections in this 2023 aSAH guideline include nursing care (Section 8.1) and recovery (Section 9). Risk factors for recurrent aSAH are also addressed (Section 10); however, risk factors for aneurysm development and rupture and management of unruptured aneurysms are not included in this guideline because these topics are addressed in a separate guideline for management of unruptured intracranial aneurysms.¹⁵ The new, important emphases in this guideline are shared decision-making, health equity, and systems of care.

Some aspects of inpatient aSAH medical care and post-aSAH rehabilitation and recovery are likely to be similar between patients with aSAH and patients with

mechanisms in the first 72 hours after aSAH that drive early brain injury also influence secondary complications and overall outcomes.²³ DCI is now hypothesized to be caused by the combined effects of large-vessel cerebral vasospasm and multiple brain injury processes triggered by aneurysm rupture and early brain injury. Mechanisms involving arteriolar constriction and cerebral microthrombosis, cortical spreading depolarization/ischemia, blood-brain barrier breakdown, cerebral autoregulation impairment, and capillary transit time heterogeneity are hypothesized to play a role in the pathophysiology.

favorable outcome in 12 months. Similar results were reported in a meta-analysis by Zhao et al,⁴⁰ which included 85 studies with 4506 patients with poor-grade aSAH. Good outcomes were observed in 39% of treated patients.

3. When controlling for degree of neurological injury, older patients compared with younger patients with aSAH have less favorable outcomes.^{28,29,31–33} In a post hoc analysis of the 405 patients included in BRAT (Barrow Ruptured Aneurysm Trial), 42% of patients >65 years of age reached functional independence at the 6-year follow-up. Although this number was significantly smaller than in the younger cohort (82%), it demonstrates that aneurysm treatment in this age group is reasonable and should be considered after discussion with the family and surrogates.³¹

Table 3. Ottawa SAH Rule

For alert patients >15 y of age with new severe nontraumatic headache reaching maximum intensity within 1 h. Patients require additional investigation for SAH if they meet any of the following criteria:	
1	Age ≥40 y
2	Neck pain or stiffness
3	Witnessed loss of consciousness
4	Onset during exertion
5	Thunderclap headache (instantly peaking pain)
6	Limited neck flexion on examination

SAH indicates subarachnoid hemorrhage.

diagnosis, these small differences are critical. LP for xanthochromia evaluation should be performed in patients presenting >6 hours from ictus in whom there is high suspicion for SAH.

- High-quality CT scanners can detect SAH with a high sensitivity, especially when the images are interpreted by fellowship-trained, board-certified neuroradiologists. (Equipment specifications for a high-quality CT scanner have been published by the American College of Radiology.⁶⁵) For patients presenting within 6 hours of headache onset who have no new neurological deficits, the lack of SAH on a noncontrast head CT is likely sufficient to exclude aSAH.^{50–53} This question was evaluated in a 2016 meta-analysis in which 8907 patients were studied. Thirteen patients had a missed SAH on head CT performed within 6 hours, leading to a sensitivity of 98.7% and specificity of 99.9%. Therefore, when performed within 6 hours of symptom onset, a negative head CT was likely to miss <1.5 in 1000 SAHs.⁵¹ It is important to note that many of these analyses do not apply to patients with atypical presentations such as primary neck pain, syncope, seizure, or new focal neurological deficit. Therefore, the lack of a classic presentation should still prompt appropriate imaging and workup.
- The Ottawa SAH Rule serves as a method to screen out individuals with a low likelihood of aSAH.⁴⁵ Application of the rule requires that patients who present with a severe headache and meet any of the criteria outlined in Table 3 may need to undergo additional testing, as directed by the treating physician. The initial study by Perry et al⁴⁵ enrolled 2131 patients, of whom 132 (6.2%) had SAH. Application of the rule was 100% sensitive but only 15.3% specific. The rule was later validated by the study authors at 6 medical centers in a prospective manner, with 1153 patients enrolled and 67 SAHs, and was found to be 100% sensitive and 13.6% specific.⁵⁵ The rule was externally validated by Bellolio et al⁵⁴ in 454 patients, of whom 9 had SAH, and it was 100% sensitive

but only 7.6% specific. Use of the Ottawa SAH Rule can therefore identify a subset of patients (albeit small) who are unlikely to have aSAH and thereby avoid additional imaging and workup that use resources and expose patients to unnecessary risk.

- CTA is widely available and often is the next diagnostic test performed when SAH is diagnosed with noncontrast CT. Certain hemorrhage patterns likely reflect a greater risk for the presence of an underlying aneurysm than others (eg, diffuse basal cistern and sylvian fissure SAH versus small-volume focal cortical SAH). For diffuse SAH, DSA is indicated for evaluation regardless of CTA results because small aneurysms or other vascular lesions may not be fully appreciated or defined on CTA imaging owing to limitations in spatial resolution.^{56–59,66}
- DSA is considered the gold-standard modality for the evaluation of cerebrovascular anatomy and aneurysm geometry and can aid in decision-making on the choice of optimal treatment modality. CTA alone may, in certain clinical settings, be used for treatment decision-making.^{60,61}

Knowledge Gaps and Future Research

- Utility of magnetic resonance imaging:* Diagnostic accuracy studies of various established and emerging magnetic resonance imaging sequences for the detection and characterization of aSAH are needed.
- Perimesencephalic SAH:* There is currently equipoise concerning the appropriate diagnostic pathway for a perimesencephalic distribution of SAH with CTA alone versus catheter-based DSA.
- Emerging technologies:* Dual-energy CT and single-photon counting CT represent novel imaging techniques that may be helpful for SAH and aneurysm detection.

5. HOSPITAL CHARACTERISTICS AND SYSTEMS OF CARE

Recommendations for Hospital Characteristics and Systems of Care Referenced studies that support recommendations are summarized in online Data Supplement 3.		
COR	LOE	Recommendations
1	B-NR	1. For patients with aSAH, timely transfer from hospitals with low case volume to higher-volume centers with multidisciplinary neurointensive care services, comprehensive stroke center capabilities, and experienced cerebrovascular surgeons/neuroendovascular interventionalists is recommended to improve outcomes. ^{67–77}
1	B-NR	2. For patients with aSAH, care should be provided in a dedicated neurocritical care unit by a multidisciplinary team. ^{78–80}

Synopsis

Patients with aSAH should undergo repair of their aneurysm as soon as it is feasible to reduce the risk of aneurysm rerupture, an event that is frequently fatal. However, the choice of treatment modality is highly nuanced. The goal of securing the aneurysm must be balanced with the risks of the procedure. Open surgical options and endovascular techniques have different advantages and disadvantages that need to be carefully weighed for each individual patient because many patient-specific factors (including patient age, aneurysm geometry and location, and presence of intraparenchymal hemorrhage) must be considered. Sometimes complete obliteration is not feasible, either technically or because procedural risks outweigh the benefits. The best outcomes for patients with SAH will be achieved when both endovascular and open surgical options are available. The quality of the evidence supporting recommendations for treatment modality is relatively limited, with a particular paucity of data on comparison of different endovascular techniques with surgical techniques or with each other. Further studies for many of these questions are necessary, and several of these are listed under "Knowledge Gaps and Future Research."

Recommendation-Specific Supportive Text

1. Early treatment of ruptured aneurysms reduces the risk of rebleeding and facilitates treatment of DCI. Timing of ruptured aneurysm treatment has been directly examined in only 1 small randomized prospective trial of patients with good-grade aSAH in the precoiling era; this study of 159 patients demonstrated that early surgery (0–3 days from SAH) resulted in lower death and dependence at 3 months compared with intermediate surgery (4–7 days) or late surgery (≥ 8 days).¹⁰³ Subsequent retrospective and prospective observational studies of both clipping and coiling, including post hoc analyses of the randomized ITJ -0.r. Alermenional stbsearh onoid5 ()TJ 0.05 TTw 0 -1.2 Td [(weAurysm trT)3-wele.andwith g lo24, 4 -

surgical treatment options by specialists with expertise, individually or as a team, in both modalities is necessary to optimally evaluate the relative risks and benefits of each treatment strategy.

7. Although older patients (>70 years of age) are often preferentially treated with coiling, in practice, there are insufficient data to support a clear benefit of coiling in this population. In the largest available RCT, ISAT, subgroup analysis by age demonstrated no benefit of coiling in the group >70 years of age, with an RR of death dependency of 1.15 (95% CI, 0.82–1.61) for coiling.¹¹³ Within the cohort of patients >65 years of age in ISAT, outcome was dependent on aneurysm location, with coiling superior in those with internal carotid and posterior communicating artery aneurysms but clipping superior for those with ruptured middle cerebral artery (MCA) aneurysms.¹¹⁴ Nonrandomized registry and observational data have also failed to demonstrate an effect of treatment modality on outcomes in the elderly (>75 years of age).^{128,129}
8. Longer life expectancy and better long-term protection from rerupture related to clipping favor consideration of clipping in young patients. Subgroup analysis from the largest available RCT, ISAT, indicates less benefit of coiling in those <50 years of age,¹¹³ and calculations based on ISAT data suggest that clip placement may be more advantageous for patients <40 years of age.¹¹⁵
9. The Cochrane review and meta-analysis of 4 RCTs of clipping versus coiling indicates that primary coiling provides higher odds of functional independence (mRS score 0–2) at 1 year, with an RR 0.77 (95% CI, 0.67–0.87) for death/dependency.¹¹⁰ The

coiling are limited, and further studies focused on these outcomes are needed.

- *Modality of treatment in patients with high-grade aSAH:* Although patients with high-grade aSAH are often preferentially treated with coiling in practice, there are insufficient robust randomized data on coiling versus clipping specifically in patients with high-grade aSAH to support clear evidence-based guidance in this population.
- *Anterior circulation aneurysms:* Ruptured MCA aneurysms, and anterior circulation bifurcation aneurysms in general, are typically considered more favorable for clipping, which is supported by limited data; however, there are insufficient data to provide definitive guidance, especially in the setting of emerging endovascular technologies.
- *Novel flow diversion technologies:* Endosaccular flow diverters and less thrombogenic intravascular flow diverters reduce the need for dual antiplatelets and attendant higher complications. Limited noncomparative data suggest protection against rebleeding and acceptable outcome with endosaccular devices, but there are insufficient comparative data and long-term outcomes to provide guidance on the use of these devices for ruptured aneurysms.
- *Evolving endovascular technologies:* In general, evolving endovascular technologies may provide additional treatment options for ruptured aneurysms, but their comparative efficacy cannot be extrapolated from prior data on other endovascular techniques such as primary coiling. New technologies should be studied prospectively relative to existing treatment options before widespread adoption.

2b	B-NR	

7.1. Anesthetic Management of Surgical and Endovascular Treatment of aSAH

Recommendations for Anesthetic Management of Surgical and Endovascular Treatment of aSAH		
Referenced studies that support recommendations are summarized in online Data Supplement 6 .		
COR	LOE	Recommendations
2a	B-R	1. In patients with aSAH, the intraoperative use of mannitol or hypertonic saline can be effective in reducing ICP and cerebral edema. ^{135,136}
2a	B-NR	2. In patients with aSAH, anesthetic goals should include minimizing postprocedural pain, nausea, and vomiting. ^{137–140}
2a	B-NR	3. In patients with aSAH, prevention of intraoperative hyperglycemia and hypoglycemia during aneurysm surgery is reasonable to improve outcomes. ^{141–147}
2a	C-LD	4. In patients with aSAH and an unsecured ruptured aneurysm, frequent intraoperative BP monitoring and BP control are reasonable to prevent ischemia and rerupture. ^{148–153}

- cytotoxic edema, which greatly increase the risk of poor outcome if associated with local and global cerebral ischemia.¹³⁵ In addition, surgical exposure and the operative procedure become more difficult. Both mannitol and hypertonic saline have been used to decrease ICP and increase cerebral blood flow (CBF) and brain relaxation.¹³⁶ Mannitol is a potent diuretic and can cause hypovolemia and hypotension, whereas hypertonic saline increases blood sodium, has minimal effect on diuresis, and can increase BP. A clinical trial to evaluate the optimal intraoperative dose of mannitol in patients with aSAH is ongoing at the time of guideline publication (ClinicalTrials.gov identifier: NCT04135456). Currently, there is insufficient evidence to recommend one therapy over the other or to affirm whether outcomes are affected.
2. Postoperative nausea and vomiting can have a negative impact after aneurysm coiling and clipping by increasing the risk of aspiration of gastric contents.¹³⁷ Incidence after aSAH has not been studied, but postoperative nausea and vomiting after craniotomy occur in 22% to 70% of patients.¹⁴⁰ A multimodal regimen of medication targeting different chemoreceptors is recommended.¹⁷² Although serotonin 5-HT₃ receptor antagonists (eg, ondansetron), steroids (eg, dexamethasone), and their combination are the most frequently used antiemetics, the addition of propofol, reduction of narcotics, and euvolemia are generally advocated. Medications that can cause confusion or sedation such as anticholinergics (eg, scopolamine) and phenothiazines (eg, promethazine) at higher doses may impair neurological examination. The use of volatile anesthetic medications for craniotomy has been associated with a higher incidence of postoperative nausea and vomiting compared with intravenous agents such as propofol,^{138,173} and dexmedetomidine may offer an advantage compared with fentanyl as an analgesic.¹³⁹ Further clinical trials comparing different regimens that significantly reduce the incidence of postoperative nausea and vomiting after aSAH would provide relevant data in this patient population.
 3. Poor perioperative glycemic control in patients with aSAH has been associated with increased risk of poor clinical outcome. The management of intraoperative glucose concentrations has not been well studied; however, the prevention of intraoperative hyperglycemia and hypoglycemia during aneurysm surgery is probably indicated.^{141,142,144–146} A post hoc analysis of IHASt (Intraoperative Hypothermia for Aneurysm Surgery Trial)¹⁴⁷ determined that commonly encountered hyperglycemia was associated with long-term changes in cognition and gross neurological function.¹⁴³
 4. Intraoperative volume status and BP goals are not well defined in intraoperative aSAH management. Numerous pathophysiological states may be present after aneurysmal rupture such as cardiovascular dysfunction, systemic inflammation, autoregulatory failure, and spreading depolarizations that can be affected by intravascular volume.¹⁵² During the intraoperative period, frequent BP monitoring and BP control are reasonable to prevent ischemia and rerupture. Hypovolemic states often necessitate additional pressor support, especially when clinical management necessitates hypertensive therapy. There are suggestions that hypovolemia (in the perioperative period) may contribute to the incidence of DCI,¹⁵² whereas hypervolemia lacks benefit^{148,149,151,153} and the rapid reduction of BP is potentially harmful.¹⁵⁰ Careful BP management needs to occur throughout the perioperative period, including transportation.
 5. Intraoperative neuromonitoring can be used to evaluate functional brain integrity in a timely manner during aneurysm surgery. Common intraoperative neuromonitoring modalities used are spontaneous electroencephalography (EEG) and transcranial Doppler (TCD).

can lead to systemic or cerebral hypoglycemia and metabolic crisis in the acutely injured brain and potentially worsen brain injury and outcome, which remains to be determined.^{232,233,239}

8.

acute phase, putting them at increased risk of developing pneumonia and leading to increased LOS and poor functional outcome and mortality at 90 days.^{258–261} Nurses are in a unique position to evaluate for dysphagia before administering anything by mouth. A systematic review and subgroup analysis that included 4528 patients found that nurse-initiated dysphagia screening and the use of formal guidelines had a significant positive effect in the prevention of pneumonia and decreased mortality rates.²⁶¹ Another large systematic review and single-blinded cluster RCT that included both patients with hemorrhagic stroke and patients with ischemic stroke reported various dysphagia screening tools and recommended the use of a validated tool as best practice within 24 hours of admission.²⁴⁶

5. Implementing stroke care protocols and order sets and providing specialized assessments to the patient with stroke require expert nursing care. A pre-/posttest-designed study found that nurses who participated in stroke competency training had improved knowledge of and adherence to stroke guidelines with a positive association with decreased LOS.²⁶³

2424a (OS.)]TJ 0 Tw (-)40 0.056 Tw 0 -1.2 (pa,iated dysphagia scre,e and paocolsfamid ((263

8.2. Monitoring and Detection of Cerebral Vasospasm and DCI

Recommendations for Monitoring and Detection of Cerebral Vasospasm and DCI		
Referenced studies that support recommendations are summarized in online Data Supplement 9 .		
COR	LOE	Recommendations
2a	B-NR	1. In patients with aSAH with suspected vasospasm or limited neurological examination, CTA or CT perfusion (CTP) can be useful to detect vasospasm and predict DCI. ^{270–275}
2a	B-NR	2. In patients with aSAH, transcranial Doppler (TCD) ultrasound monitoring is reasonable to detect vasospasm and predict DCI. ^{253,276–280}
2a	B-NR	3. In patients with high-grade aSAH, continuous EEG (cEEG) monitoring can be useful to predict DCI. ^{276,280–292}
2b	B-NR	4. In patients with high-grade aSAH, invasive monitoring of brain tissue oxygenation, lactate/pyruvate ratio, and glutamate may be considered to predict DCI. ^{293–305}

Synopsis

Narrowing of the cerebral arteries (cerebral vasospasm) occurs frequently in patients with aSAH and is associated with DCI and infarction. DCI occurs in ≈30% of patients, mostly between days 4 and 14 after aSAH. Clinical deterioration due to DCI has been defined as the occurrence of focal neurological impairment or a decrease of at least 2 points on the GCS.^{306–308} This should last for at least 1 hour, is not apparent immediately after aneurysm occlusion, and cannot be attributed to other causes. New cerebral infarction has been defined as the presence of cerebral infarction on CT or magnetic resonance imaging scan of the brain within 6 weeks after aSAH not attributable to other causes.^{306–308} Diagnosis of DCI can be challenging, and although serial neurological examinations are important (see Section 8.1), they are of limited value in patients with high-grade aSAH. Several diagnostic tools have been used to identify arterial narrowing and cerebral perfusion abnormalities that may help predict DCI. The most commonly available techniques include TCD ultrasound,^{253,276–280}

diagnostic accuracy of cEEG for DCI in patients with high-grade aSAH following the Standards for Reporting of Diagnostic Accuracy Studies.³¹⁵ The study protocol consisted of clinical neurophysiologists prospectively reporting prespecified EEG alarms: (1) decreasing relative alpha power variability, (2) decreasing alpha-to-delta power ratio, (3) worsening focal slowing, or (4) late-appearing epileptiform abnormalities. The diagnostic reference

techniques to target different levels of the cerebral vasculature.³⁷³

5. Angioplasty offers a mechanical option for improving perfusion in patients with severe vasospasm. Historically, angioplasty was performed with endovascular balloons and was confined to proximal vasculature. The choice between compliant and noncompliant balloons remains operator dependent.³⁵⁶ A poor angiographic response to angioplasty is associated with recurrent vasospasm and risk of cerebral infarction.³³⁷ Particular care must be taken with cerebral angioplasty given the high mortality associated with vessel rupture, although contemporary safety profiles are favorable. Limited direct comparisons exist between angioplasty and vasodilator therapy.⁵

have shown promise, treatment in patients with aSAH requires further studies.

- *Drainage via lumbar drain or EVD:* Such drainage allows expedited removal of blood products from the CSF, with computational models showing effectiveness. Available trial data suggest that drainage through a lumbar drain reduces the incidence of DCI, despite trials being population and center limited. The role of a lumbar drain in aSAH is being actively investigated.
- *Cisternal fibrinolytic and spasmolytic medication:* These medications have recently been introduced to help clear subarachnoid blood in the CSF space. An ongoing double-blinded clinical trial is underway to detect effectiveness through administration by cisternal lavage.

8.4. Management of Hydrocephalus Associated With aSAH

Recommendations for Management of Hydrocephalus Associated With aSAH		

key components defined in the literature to be considered and included in a bundled EVD protocol.

3. According to the literature, aSAH-associated persistent or chronic shunt-dependent hydrocephalus occurs in 8.9% to 48% of patients with aSAH.⁴⁰⁰ Significant predictors of shunt dependency include poor admission neurological grade, increased age, acute hydrocephalus, high Fisher grades, presence of intraventricular hemorrhage, rebleeding, ruptured posterior circulation artery aneurysm, anterior communicating artery aneurysm, surgical clipping, endovascular coiling, cerebral vasospasm, meningitis, and a prolonged period of EVD.^{12,397–400} According to a large observational study, clipping and coiling of ruptured and unruptured cerebral aneurysms were associated with similar incidences of ventricular shunt placement for hydrocephalus.³⁹⁸ Last, permanent CSF diversion was shown to improve neurological outcome after aSAH.^{12,397–400}
- 4.

3: Harm	B-NR	4. In patients with aSAH, phenytoin for seizure prevention and/or antiseizure prophylaxis is associated with excess morbidity and mortality. ^{407–411,413–415}
Patients who present with seizures		
2a	B-NR	5. In patients with aSAH who present with seizures, treatment with antiseizure medications for ≤7 days is reasonable to reduce seizure-related complications in the perioperative period. ^{411,416,417}
3: No benefit	B-NR	6. In patients with aSAH without prior epilepsy who present with seizures, treatment with antiseizure medications beyond 7 days is not effective for reducing future SAH-associated seizure risk. ^{408,410,411}

Synopsis

Although the incidence of aSAH-associated seizures is relatively common, an understanding of the management of seizures is poorly supported by randomized, controlled studies. Since the 2012 aSAH guideline,¹² meta-analyses, single-center studies, and evaluations of next-generation antiseizure medications are the best sources from which to obtain management recommendations. Although seizure-like episodes have been reported in up to 26% patients with aSAH, a better understanding of the incidence of seizures has been attained with improved EEG monitoring capability. More recent studies suggest a lower seizure incidence of 7.8% to 15.2%.^{410,411,417} Early and late postoperative seizures have an incidence of 2.3% and 5.5%, respectively.⁴¹¹ In patients with aSAH who present with seizures, the use of antiseizure medications for <7 days is reasonable to reduce delayed seizure or hemorrhage risk.^{411,416,417} Endovascular coil embolization compared with neurosurgical clipping seems to be associated with a lower incidence of late seizures.^{113,411} In addition to the surgical management of aneurysms, clinical grade (HH grade ≥

many instances.⁴²² Studies that discuss the effect of antiseizure medications on global functional outcomes are inconclusive.^{407,423} Poorer cognitive outcomes have been related to phenytoin administration. Whether this increased morbidity is related to an effect on DCI through metabolic competition with nimodipine or undiagnosed transaminase elevations is unclear. Use of newer-generation antiseizure medications that may be more effective or less toxic than phenytoin remains a topic of discussion.⁴²⁴ A single-blinded randomized study of levetiracetam versus phenytoin demonstrated the same outcomes with respect to mortality or seizure control as evaluated by cEEG. Therapy with levetiracetam resulted in a lower incidence of adverse effects as evaluated by the Glasgow Outcome Scale–Extended and Disability Rating Scale. The excess morbidity associated with the use of phenytoin should prompt the use of alternative antiseizure medications.⁴¹⁵

5. An important distinction in the management of patients with aSAH-associated seizure is whether seizure is a component of the patient presentation. This has resulted in literature and subsequent recommendations that are based on onset, early, and late seizures. Onset seizures occur at the time of the hemorrhage; early seizures occur during the first week; and late seizures are either post-operative or occur after 1 week. Onset seizures have been found to predict poor outcome after aSAH.⁴¹⁷ The possibility of preventing nonconvulsive status or rerupture of an unsecured aneurysm

1	B-NR	3. In patients with aSAH and depression,

with differences in the dose, duration, and type of selective serotonin reuptake inhibitors used. Among patients with stroke who were on selective serotonin reuptake inhibitors, there was a reduction in the proportion of patients with post-stroke depression (RR, 0.75; 3 studies with high-quality evidence including 5907 participants).⁴³⁴ In another review (n=8 trials), pharmacological interventions (n=1025 participants) decreased depressive symptoms at the end of treatment.⁴³³ The use of selective serotonin reuptake inhibitors is appropriate for patients with preexisting symptoms of depression. Various psychosocial interventions that have been studied for stroke survivors include music therapy, mindfulness, and motivational interviewing. Although data supporting the efficacy of these interventions are limited, they are

epilepticus) have been treated, few interventions have been studied to promote consciousness recovery in the acute setting. Cognitive motor dissociation may be seen in 15% of patients with severe acute brain injuries, including aSAH,⁴⁵⁹ as determined by

Synopsis

Long-term recovery extends beyond the first 3 months in individuals with aSAH. Neurological deficits can result in an increased incidence of depression, anxiety, and cognitive impairments, resulting in changes in familial roles and a negative impact on overall QOL for months to years after the initial injury. These recommendations focus on evaluations done for the purpose of identifying treatable cognitive and behavioral sequelae after aSAH. The variable yield of testing, including the potential influence of caregiver input, means that clinicians should exercise discernment when initiating treatment plans.

Recommendation-Specific Supportive Text

1. Identification and treatment of psychological and sexual sequelae can have a positive impact on QOL after aSAH. Screening tools to evaluate patterns of depression, anxiety, mobility, and activities of daily living detailed in the literature include the State Trait Anxiety Inventory, Hospital Anxiety and Depression Scale, Telephone Interview for Cognitive Status, and Barthel Index at 6 months, 1 year, and 2 years.⁴⁶² Use of the International Index of Erectile Function and the Female Sexual Function Index within the first 4 years⁴⁶⁵ is recommended to evaluate sexual dysfunction in men and women, respectively. For long-term follow-up after aSAH, the Hospital Anxiety and Depression Scale can be used within the first 8.9 years⁴⁶³ to examine anxiety and depression incidence, and the EuroQol-5D can be used within the first 10 years to evaluate health-related QOL.⁴⁶¹ Furthermore, the 36-item Short Form can be used within 4.7 years to evaluate outcomes in 8 domains: physical and social functioning, role limitations because of physical or emotional problems, bodily pain, mental and general health perception, and vitality.⁴⁶⁴ Although the time frame for use of these screening tools is described here in accordance with the studies, their use can be considered beyond the suggested time frames for individual patients.
2. After aSAH, cognitive dysfunction is an important cause of disability. The most common cognitive complaints include mental slowness, memory, and attention difficulties. Although most deficits improve, ≈50% of patients with aSAH continue to experience cognitive difficulties for a year.^{469,470}

Appendix 1. Continued

Writing group member	Employment	Research grant/other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other	Voting recusals by section‡
Steven W. Hetts	University of California San Francisco	Stryker‡; Siemens Medical Solutions†	None	None	None	Kaneka Pharma America LLC*	None	7. Surgical and Endovascular Methods for Treatment of Ruptured Cerebral Aneurysms
Nneka L. Ifejika	University of Texas Southwestern Medical Center	None	None	None	None	None	None	
Regina Johnson	NA	None	None	None	None	None	None	
Kiffon M. Keigher	Advocate Aurora Health System and Rush University College of Nursing	None	None	None	None	None	None	
Thabele M. Leslie-Mazwi	University of Washington	None	None	None	None	None	None	
Brandon P. Lucke-Wold	University of Florida	None	None	None	None	None	None	
Alejandro A. Rabinstein	Mayo Clinic	None	None	None	None	None	None	
Steven A. Robicsek	University of Florida	None	None	None	None	None	Heineman-Robicsek Foundation* (fiduciary officer)	
Christopher J. Stapleton	Massachusetts General Hospital	Genentech‡; Penumbra‡; Route 92†	None	None	None	None	None	7. Surgical and Endovascular Methods for Treatment of Ruptured Cerebral Aneurysms
Jose I. Suarez	Johns Hopkins University School of Medicine	None	None	None	None	None	None	
Stavropoula I. Tjoumakaris	Thomas Jefferson University Hospital at Sidney Kimmel Medical College	None	None	None	None	MicroVention*; Medtronic†	None	7. Surgical and Endovascular Methods for Treatment of Ruptured Cerebral Aneurysms
Babu G. Welch	University of Texas Southwestern Medical Center	Stryker*; MicroVention*	None	None	None	MicroVention*; Stryker Corp‡; Medtronic*	None	7. Surgical and Endovascular Methods for Treatment of Ruptured Cerebral Aneurysms

This table represents the relationships of writing group members that may be perceived as actual or reasonably perceived conflicts of interest as reported on the Disclosure Questionnaire, which all members of the writing group are required to complete and submit. A relationship is considered to be "significant" if (a) the person receives \$5000 or more during any 12-month period, or 5% or more of the person's gross income; or (b) the person owns 5% or more of the voting stock or share of the entity or owns \$5000 or more of the fair market value of the entity. A relationship is considered to be "modest" if it is less than "significant" under the preceding definition.

*Modest (<\$5000).

†Significant (≥\$5000).

‡Writing committee members are required to recuse themselves from voting on sections to which their specific relationships with industry and other entities may apply.

Appendix 2. Continued

Peer reviewer								

CLINICAL STATEMENTS AND GUIDELINES

(Continued)

Peer reviewer	Employment	Research grant	Other research support	Speakers' bureau/honoraria	Expert witness	Ownership interest	Consultant/advisory board	Other
Aarti Sarwal	Wake Forest Baptist Health; Wake Forest School of Medicine	Butterfly Network, Inc.; C. R. Bard, Inc. & Subsidiaries†	University of Technology, Sydney (Intellectual Property - Other Intellectual Property: Compensation for reviewing Thesis for a Master's project)*; Society of Critical Care Medicine (Intellectual Property - Other Intellectual Property: Social Media Editor for Critical Care Medicine)*	None	None	None	CVR Global (Independent Contractor - Site Investigator for multicenter clinical trial conducted by CVR Global)*; C. R. Bard, Inc. & Subsidiaries (Independent Contractor - Site investigator for multicenter trial sponsored by Bard)*; Biogen, Inc. (Independent Contractor - Site investigator for multicenter trial conducted by Biogen. Monies paid to Department for costs associated with multicenter clinical trial. No direct monies or support paid to me.)*	Intensive Care Society (Travel; Location: Belfast, Ireland. Reimbursement for travel to speak at ICS)*; Travelkt7S0 - 0 -Fi 0 0 y OFTJ 02 Tw -1.28ducted

REFERENCES

1. Etminan N, Chang HS, Hackenberg K, de Rooij NK, Vergouwen MDI, Rinkel GJE, Algra A. Worldwide incidence of aneurysmal subarachnoid hemorrhage according to region, time period, blood pressure, and smoking prevalence in the population: a systematic review and meta-analysis. *JAMA Neurol.* 2019;76:588–597. doi: 10.1001/jamaneurol.2019.0006
2. Tsao CW, Aday AW, Almarzooq ZI, Anderson CAM, Arora P, Avery CL, Baker-Smith CM, Beaton AZ, Boehme AK, Buxton AE, et al: on behalf of the American Heart Association Council on Epidemiology and Prevention Statistics Committee and Stroke Statistics Subcommittee. Heart disease and stroke statistics—2023 update: a report from the American Heart Association [published correction appears in *Circulation.* 2023;147:e622]. *Circulation.* 2023;147:e93–e621. doi: 10.1161/CIR.0000000000001123
3. GBD 2019 Stroke Collaborators. Global, regional, and national burden of stroke and its risk factors, 1990-2019: a systematic analysis for the Global Burden of Disease Study 2019. *Lancet Neurol.* 2021;20:795–820. doi: 10.1016/S1474-4422(21)00252-0
4. Matsuda S, Ikawa F, Hidaka T, Yamaguchi S, Inagawa T, Horie N, Kurisu K, Akiyama Y, Goto Y, Nakayama T, et al; JIS Study Group. Recent declining trend of incidence rate of subarachnoid hemorrhage in Shimane, Japan: the Japan Incidence of Subarachnoid Hemor-

14. Derdeyn CP, Zipfel GJ, Albuquerque FC, Cooke DL, Feldmann E, Sheehan JP, Torner JC; on behalf of the American Heart Association Stroke Council. Management of brain arteriovenous malformations: a scientific statement for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2017;48:e200–e224. doi: 10.1161/STR.000000000000134
15. Thompson BG, Brown RD Jr, Amin-Hanjani S, Broderick JP, Cockroft KM, Connolly ES Jr, Duckwiler GR, Harris CC, Howard VJ, Johnston SC, et al; on behalf of the American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, and Council on Epidemiology and Prevention. Guidelines for the management of patients with unruptured intracranial aneurysms: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. *Stroke*. 2015;46:2368–2400. doi: 10.1161/STR.0000000000000070
16. Bederson JB, Connolly ES Jr, Batjer HH, Dacey RG, Dion JE, Diringer MN, Duldner JE Jr, Harbaugh RE, Patel AB, Rosenwasser RH; American Heart Association. Guidelines for the management of aneurysmal subarachnoid hemorrhage: a statement for healthcare professionals from a special writing group of the Stroke Council, American Heart Association [published correction appears in *Stroke*. 2009;40:e518]. *Stroke*. 2009;40:994–1025. doi: 10.1161/STROKEAHA.108.191395
17. Bor AS, Rinkel GJ, Adami J, Koffijberg H, Ekbom A, Buskens E, Blomqvist P, Granath F. Risk of subarachnoid haemorrhage according to number of affected relatives: a population based case-control study. *Brain*. 2008;131:2662–2665. doi: 10.1093/brain/awn187
18. Zuurbier CCM, Bourcier R, Constant D, Beaufils P, Redon R, Desal H, Bor ASE, Lindgren AE, Rinkel GJE, Greving JP, Ruigrok YM; ICAN Investigat g -1: igroku3r.(a popula)Tj nt Dit BeaufilsG]TJ /T1_1 1 Tf O T ac8x4 23 0 Tddd1o v1.286 Td [(group)0.6 (of)0.5 (the)0.5 (Stroke)0.6 (Council,)0.6 iu C

51. Dubosh NM, Bellolio MF, Rabinstein AA, Edlow JA. Sensitivity of early brain computed tomography to exclude aneurysmal subarachnoid hemorrhage: a systematic review and meta-analysis. *Stroke*. 2016;47:750–755. doi: 10.1161/STROKEAHA.115.011386
52. Backes D, Rinkel GJ, Kemperman H, Linn FH, Vergouwen MD. Time-dependent test characteristics of head computed tomography in patients suspected of nontraumatic subarachnoid hemorrhage. *Stroke*. 2012;43:2115–2119. doi: 10.1161/STROKEAHA.112.658880
53. Blok KM, Rinkel GJ, Majoie CB, Hendrikse J, Braaksma M, Tijssen CC, Wong YY, Hofmeijer J, Extercatte J, Kerklaan B, et al. CT within 6 hours of headache onset to rule out subarachnoid hemorrhage in nonacademic hospitals. *Neurology*. 2015;84:1927–1932. doi: 10.1212/WNL.0000000000001562
54. Bellolio MF, Hess EP, Gilani WI, VanDyck TJ, Ostby SA, Schwarz JA, Lohse CM, Rabinstein AA. External validation of the Ottawa subarachnoid hemorrhage clinical decision rule in patients with acute headache. *Am J Emerg Med*. 2015;33:244–249. doi: 10.1016/j.ajem.2014.11.049
55. Perry JJ, Sivilotti MLA, Sutherland J, Hohl CM, Emond M, Calder LA, Vaillancourt C, Thiriganasambandamoorthy V, Lesiuk H, Wells GA, et al. Validation of the Ottawa Subarachnoid Hemorrhage Rule in patients with acute headache. *CMAJ*. 2017;189:E1379–E1385. doi: 10.1503/cmaj.170072
56. Agid R, Andersson T, Almqvist H, Willinsky RA, Lee SK, terBrugge KG, Farb RI, Soderman M. Negative CT angiography findings in patients with spontaneous subarachnoid hemorrhage: when is digital subtraction angiography still needed? *AJNR Am J Neuroradiol*. 2010;31:696–705. doi: 10.3174/ajnr.A1884
57. Catapano JS, Lang MJ, Koester SW, Wang DJ, DiDomenico JD, Fredrickson VL, Cole TS, Lee J, Lawton MT, Ducruet AF, et al. Digital subtraction cerebral angiography after negative computed tomography angiography findings in non-traumatic subarachnoid hemorrhage.

87. Baharoglu MI, Germans MR, Rinkel GJ, Algra A, Vermeulen M, van Gijn J, Roos YB. Antifibrinolytic therapy for aneurysmal subarachnoid haemorrhage. *Cochrane Database Syst Rev*. 2013;2013:CD001245. doi: 10.1002/14651858.CD001245.pub2
88. Vergouwen MD, Jong-Tjien-Fa AV, Algra A, Rinkel GJ. Time trends in causes of death after aneurysmal subarachnoid hemorrhage: A hospital-based study. *Neurology*. 2016;86:59–63. doi: 10.1212/WNL.0000000000002239
89. Kassell NF, Torner JC, Jane JA, Haley EC Jr, Adams HP. The International Cooperative Study on the Timing of Aneurysm Surgery, part 2: surgical results. *J Neurosurg*. 1990;73:37–47. doi: 10.3171/jns.1990.73.1.0037
90. Wijdicks EF, Vermeulen M, Murray GD, Hijdra A, van Gijn J. The effects of treating hypertension following aneurysmal subarachnoid hemorrhage. *Clin Neurol Neurosurg*. 1990;92:111–117. doi: 10.1016/0303-8467(90)90085-j
91. Ohkuma H, Tsurutani H, Suzuki S. Incidence and significance of early aneurysmal rebleeding before neurosurgical or neurological management. *Stroke*. 2001;32:1176–1180. doi: 10.1161/01.str.32.5.1176
92. Calviere L, Gathier CS, Rafiq M, Koopman I, Rousseau V, Raposo N, Albuquer JF, Viguier A, Geeraerts T, Cognard /T1rj rysmal rT; T, Cognard /42 (F)2Vuuae286 Td [(hypertensiosubarac)20 (hnoïd hemorrhage.)]TJ /T1_ Td [(9)-Ont. Fdiatin

-
122. Bsat S, Bsat A, Tamim H, Chanbour H, Alomari SO, Houshiemy MNE, Moussalem C, Omeis I. Safety of stent-assisted coiling for the treatment of wide-necked ruptured aneurysm: a systematic literature review and

- of poor-grade subarachnoid hemorrhage patients increases the diagnosis of deep venous thrombosis. *Neurol Res*. 2008;30:889–892. doi: 10.1179/174313208X327946
193. Manoel AL, Turkel-Parrella D, Germans M, Kouzmina E, Almendra Pda S, Marotta T, Spears J, Abrahamson S. Safety of early pharmacological thromboprophylaxis after subarachnoid hemorrhage. *Can J Neurol Sci*. 2014;41:554–561. doi: 10.1017/cjn.2014.16
194. Bilotta F, Spinelli A, Giovannini F, Doronzio A, Delfini R, Rosa G. The effect of intensive insulin therapy on infection rate, vasospasm, neurologic outcome, and mortality in neurointensive care unit after intracranial aneurysm clipping in patients with acute subarachnoid hemorrhage: a randomized prospective pilot trial. *J Neurosurg Anesthesiol*. 2007;19:156–160. doi: 10.1097/ANA.0b013e3180338e69
195. Lanzino G, Kassell NF, Germanson T, TruskoBuFF0009>>> BDC -2. 0 (etyelw (WBUFF0. Pl))Ta glu95 Tw 0 -1.286 Td [Almendra P]41 (da Scose level(hn)0.0.05 (mhnoïd h 195.

- therapy for symptomatic vasospasm after subarachnoid hemorrhage. *Crit Care Med*. 2000;28:824–829. doi: 10.1097/00003246-200003000-00035
229. Uozumi Y, Mizobe T, Miyamoto H, Ashida N, Katsube T, Tatsumi S, Nakamura M, Kohmura E. Decreased serum sodium levels predict symptomatic vasospasm in patients with subarachnoid hemorrhage. *J Clin Neurosci*. 2017;46:118–123. doi: 10.1016/j.jocn.2017.08.037
 230. Zheng B, Qiu Y, Jin H, Wang L, Chen X, Shi C, Zhao S. A predictive value of hyponatremia for poor outcome and cerebral infarction in high-grade aneurysmal subarachnoid haemorrhage patients. *J Neurol Neurosurg Psychiatry*. 2011;82:213–217. doi: 10.1136/jnnp.2009.180349
 231. Alaraj A, Hussein AE, Esfahani DR, Amin-Hanjani S, Aletich VA, Charbel FT. Reducing length of stay in aneurysmal subarachnoid hemorrhage: a three year institutional experience. *J Clin Neurosci*. 2017;42:66–70. doi: 10.1016/j.jocn.2017.03.049
 232. Finfer S, Chittock DR, Su SY, Blair D, Foster D, Dhingra V, Bellomo R, Cook D, Dodek P, Henderson WR, et al: NICE-SUGAR Study Investigators. Intensive versus conventional glucose control in critically ill patients. *N Engl J Med*. 2009;360:1283–1297. doi: 10.1056/NEJMoa0810625
 233. Oddo M, Schmidt JM, Carrera E, Badjatia N, Connolly ES, Presciutti M, Ostapkovich ND, Levine JM, Le Roux P, Mayer SA. Impact of tight glycemic control on cerebral glucose metabolism after severe brain injury: a microdialysis study. *Crit Care Med*. 2008;36:3233–3238. doi: 10.1097/CCM.0b013e31818f4026
 234. Nakagawa I, Hironaka Y, Nishimura F, Takeshima Y, Matsuda R, Yamada S, Motoyama Y, Park YS, Nakase H. Early inhibition of natriuresis suppresses symptomatic cerebral vasospasm in patients with aneurysmal subarachnoid hemorrhage. *Cerebrovasc Dis*. 2013;35:131–137. doi: 10.1159/000346586
 235. Mori T, Katayama Y, Kawamata T, Hirayama T. Improved efficiency of hypervolemic therapy with inhibition of natriuresis by fludrocortisone in patients with aneurysmal subarachnoid hemorrhage. *J Neurosurg*. 1999;91:947–952. doi: 10.3171/jns.1999.91.6.0947
 236. Hasan D, Vermeulen M, Wijdicks EF, Hijdra A, van Gijn J. Management problems in acute hydrocephalus after subarachnoid hemorrhage. *Stroke*. 1989;20:747–753. doi: 10.1161/01.str.20.6.747
 237. Schlenk F, Graetz D, Nagel A, Schmidt M, Sarrafzadeh AS. Insulin-related decrease in cerebral glucose despite normoglycemia in aneurysmal subarachnoid hemorrhage. *Crit Care*. 2008;12:R9. doi: 10.1186/cc6776
 238. Fernandez A, Schmidt JM, Claassen J, Pavlicova M, Huddleston D, Kreiter KT, Ostapkovich ND, Kowalski RG, Parra A, Connolly ES, et al. Fever after subarachnoid hemorrhage: risk factors and impact on outcome. *Neurology*. 2007;68:1013–1019. doi: 10.1212/01.wnl.0000258543.45879.f5
 239. Schlenk F, Sarrafzadeh AS. Is continuous insulin treatment safe in aneurysmal subarachnoid hemorrhage? *Vasc Health Risk Manag*. 2008;4:885–891. doi: 10.2147/vhrm.s1924
 240. Rosenwasser RH, Delgado TE, Buchheit WA, Freed MH. Control of hypertension and prophylaxis against vasospasm in cases of subarachnoid hemorrhage: a preliminary report. *Neurosurgery*. 1983;12:658–661. doi: 10.1227/00006123-198306000-00012
 241. Lee SH, Lim JS, Kim N, Yoon BW. Effects of admission glucose level on mortality after subarachnoid hemorrhage: a comparison between short-term and long-term mortality. *J Neurol Sci*. 2008;275:18–21. doi: 10.1016/j.jns.2008.05.024
 242. Broessner G, Lackner P, Fischer M, Beer R, Helbok R, Pfausler B, Schneider D, Schmutzhard E. Influence of prophylactic, endovascularly based normothermia on inflammation in patients with severe cerebrovascular disease: a prospective, randomized trial. *Stroke*. 2010;41:2969–2972. doi: 10.1161/STROKEAHA.110.591933
 243. Allen D, Rixson L. How has the impact of "care pathway technologies" on service integration in stroke care been measured and what is the strength of the evidence to support their effectiveness in this respect? *Int J Evid Based Healthc*. 2008;6:78–110. doi: 10.1111/j.1744-1609.2007.00098.x
 244. Middleton S, McElduff P, Ward J, Grimshaw JM, Dale S, D'Este C, Drury P, Griffiths R, Cheung NW, Quinn C, et al: QASC Trialists Group. Implementation of evidence-based treatment protocols to manage fever, hyperglycaemia, and swallowing dysfunction in acute stroke (QASC): a cluster randomised controlled trial. *Lancet*. 2011;378:1699–1706. doi: 10.1016/S0140-6736(11)61485-2
 245. Anetsberger A, Gempt J, Blobner M, Ringel F, Bogdanski R, Heim M, Schneider G, Meyer B, Schmid S, Ryang YM, et al. Impact of goal-directed therapy on delayed ischemia after d(24snNeuysmalr subarac)20.1 (hnoid hemot)]TJ O Tw O -1.286 Td rrhage: randomized controlled trial. *Stroke*. 2011;42:1280–1286. doi: 10.1161/STROKEAHA.110.2280
- 6 Middleton d(24S()05 McElduff)065 (P)103 ()05 (Drury)05 (P)103 ()05 D'Este C,Cadilhace , 24S()TJ 0.912 Tw O -1.286 Td [his(of

-
300. Veldeman M, Albanna W, Weiss M, Conzen C, Schmidt TP, Schulze-Steinen H, Wiesmann M, Clusmann H, Schubert GA. Invasive neuromonitoring with an extended definition of delayed cerebral ischemia is associated with improved outcome after poor-grade subarachnoid hemorrhage. *J Neurosurg*. 2020;134:1527–1534. doi: 10.3171/2020.3.JNS20375
 301. Skjoth-Rasmussen J, Schulz M, Kristensen SR, Bjerre P. Delayed neurological deficits detected by an ischemic pattern in the extracellular cerebral metabolites in patients with aneurysmal subarachnoid hemorrhage. *J Neurosurg*. 2004;100:8–15. doi: 10.3171/jns.2004.100.1.0008
 302. Unterberg AW, Sakowitz OW, Sarrafzadeh AS, Benndorf G, Lanksch WR. Role of bedside microdialysis in the diagnosis of cerebral vasospasm following aneurysmal subarachnoid hemorrhage. *J Neurosurg*. 2001;94:740–749. doi: 10.3171/jns.2001.94.5.0740
 303. Kett-White R, Hutchinson PJ, Al-Rawi PG, Gupta AK, Pickard JD, Kirkpatrick PJ. Adverse cerebral events detected after subarachnoid hemorrhage using brain oxygen and microdialysis probes. *Neurosurgery*. 2002;50:1213–1221. doi: 10.1097/00006123-200206000-00008
 - 304.

368. Smith WS, Dowd CF, Johnston SC, Ko NU, DeArmond SJ, Dillon WP, Setty D, Lawton MT, Young WL, Higashida RT, et al. Neurotoxicity of intra-arterial papaverine preserved with chlorobutanol used for the treatment of cerebral vasospasm after aneurysmal subarachnoid hemorrhage. *Stroke*. 2004;35:2518–2522. doi: 10.1161/01.STR.0000144682.00822.83
369. Rosenberg N, Lazzaro MA, Lopes DK, Prabhakaran S. High-dose intra-arterial nicardipine results in hypotension following vasospasm treatment in subarachnoid hemorrhage. *Neurocrit Care*. 2011;15:400–404. doi: 10.1007/s12028-011-9537-4
370. McAuliffe W, Townsend M, Eskridge JM, Newell DW, Grady MS, Winn HR. Intracranial pressure changes induced during papaverine infusion for treatment of vasospasm. *J Neurosurg*. 1995;83:430–434. doi: 10.3171/jns.1995.83.3.0430
371. Pandey P, Steinberg GK, Dodd R, Do HM, Marks MP. A simplified method for administration of intra-arterial nicardipine for vasospasm with cervical catheter infusion. *Neurosurgery*. 2012;71:77–85. doi: 10.1227/NEU.0b013e3182426257
372. von der Brölie C, Doukas A, Stopfer A, Larsen N, Mehdorn M, Synowitz M, Jansen O. Clinical course and monitoring parameters after continuous interventional intra-arterial treatment in patients with refractory cerebral vasospasm. *World Neurosurg*. 2017;100:504–513. doi: 10.1016/j.wneu.2016.12.110
373. Cooke D, Seiler D, Hallam D, Kim L, Jarvik JG, Sekhar L, Ghodke B. Does treatment modality affect vasospasm distribution in aneurysmal subarachnoid hemorrhage: differential use of intra-arterial interventions for cerebral vasospasm in surgical clipping and endovascular coiling populations. *J Neurointerv Surg*. 2010;2:139–144. doi: 10.1136/jnis.2009.000919
374. Liu T, Zhong S, Zhai Q, Zhang X, Jing H, Li K, Liu S, Han S, Li L, Shi X, et al. Optimal course of statins for patients with aneurysmal subarachnoid hemorrhage: is longer treatment better? A meta-analysis of randomized controlled trials. *Front Neurosci*. 2021;15:757505. doi: 10.3389/fnins.2021.757505
375. Su SH, Xu W, Hai J, Wu YF, Yu F. Effects of statins-use for patients with aneurysmal subarachnoid hemorrhage: a meta-analysis of randomized controlled trials. *Sci Rep*. 2014;4:4573. doi: 10.1038/srep04573
376. Rabinstein AA. Vasospasm and statin therapy: yet another cautionary tale. *Neurocrit Care*. 2010;12:310–312. doi: 10.1007/s12028-009-9267-z
377. Odom MJ, Zuckerman SL, Mocco J. The role of magnesium in the management of cerebral vasospasm. *Neurol Res Int*. 2013;2013:943914. doi: 10.1155/2013/943914
378. Wong GK, Poon WS, Chan MT, Boet R, Gin T, Ng SC, Zee BC; IMASH Investigators. Intravenous Magnesium Sulphate for Aneurysmal Subarachnoid Hemorrhage (IMASH): a randomized, double-blinded, placebo-controlled, multicenter phase III trial. *Stroke*. 2010;41:921–926. doi: 10.1161/STROKEAHA.109.571125
379. Ma L, Liu WG, Zhang JM, Chen G, Fan J, Sheng HS. Magnesium sulphate in the management of patients with aneurysmal subarachnoid haemorrhage: a meta-analysis of prospective controlled trials. *Brain Inj*. 2010;24:730–735. doi: 10.3109/02699051003610516
380. Faust K, Horn P, Schneider UC, Vajkoczy P. Blood pressure changes after aneurysmal subarachnoid hemorrhage and their relationship to cerebral vasospasm and clinical outcome. *Clin Neurol Neurosurg*. 2014;125:36–40. doi: 10.1016/j.clineuro.2014.06.023
381. Teping F, Albanna W, Clusmann H, Schulze-Steinen H, Mueller M, Hoellig A, Schubert GA. Spontaneous elevation of blood pressure after SAH: an epiphenomenon of disease severity and demand, but not a surrogate for outcome? *Neurocrit Care*. 2018;29:214–224. doi: 10.1007/s12028-018-0528-6
382. Lakhali K, Hivert A, Alexandre PL, Fresco M, Robert-Edan V, Rodie-Talbere PA, Ambrosi X, Bourcier R, Rozec B, Cadiet J. Intravenous milrinone for cerebral vasospasm in subarachnoid hemorrhage: the MILRISPASM controlled before-after study. *Neurocrit Care*. 2021;35:669–679. doi: 10.1007/s12028-021-01331-z
383. Bernier TD, Schontz MJ, Izzy S, Chung DY, Nelson SE, Leslie-Mazwi TM, Henderson GV, Dasenbrock H, Patel N, Aziz-Sultan MA, et al. Treatment of subarachnoid hemorrhage-associated delayed cerebral ischemia with milrinone: a review and proposal. *J Neurosurg Anesthesiol*. 2021;33:195–202. doi: 10.1097/ANA.0000000000000755
384. Ransom ER, Mocco J, Komotar RJ, Sahni D, Chang J, Hahn DK, Kim GH, Schmidt JM, Sciacca RR, Mayer SA, et al. External ventricular drainage response in poor grade aneurysmal subarachnoid hemorrhage: effect on preoperative grading and prognosis. *Neurocrit Care*. 2007;6:174–180. doi: 10.1007/s12028-007-0019-7
385. McIver JI, Friedman JA, Wijidicks EF, Piepgras DG, Pichelmann MA, Toussaint LG 3rd, McClelland RL, Nichols DA, Atkinson JL. Preoperative ventriculostomy and rebleeding after aneurysmal subarachnoid hemorrhage. *J Neurosurg*. 2002;97:1042–1044. doi: 10.3171/jns.2002.97.5.1042
386. Connolly ES Jr, Kader AA, Frazzini VI, Winfree CJ, Solomon RA. The safety of intraoperative lumbar subarachnoid drainage for acutely ruptured intracranial aneurysm: technical note. *Surg Neurol*. 1997;48:338–342. doi: 10.1016/s0090-3019(96)00472-7
387. Rajshekhar V, Harbaugh RE. Results of routine ventriculostomy with external ventricular drainage for acute hydrocephalus following subarachnoid haemorrhage. *Acta Neurochir (Wien)*. 1992;115:8–14. doi: 10.1007/BF01400584
388. Olson DM, Zomorodi M, Britz GW, Zomorodi AR, Amato A, Graffagnino C. Continuous cerebral spinal fluid drainage associated with complications in patients admitted with subarachnoid hemorrhage. *J Neurosurg*. 2013;119:974–980. doi: 10.3171/2013.6.JNS122403
389. Williams TA, Leslie GD, Dobb GJ, Roberts B, van Heerden PV. Decrease in proven ventriculitis by reducing the frequency of cerebrospinal fluid sampling from extraventricular drains. *J Neurosurg*. 2011;115:1040–1046. doi: 10.3171/2011.6.JNS11167
390. Flint AC, Rao VA, Renda NC, Faigles BS, Lasman TE, Sheridan W. A simple protocol to prevent external ventricular drain infections. *Neurosurgery*. 2013;72:993–999. doi: 10.1227/NEU.0b013e31828e8dfc
391. Dasic D, Hanna SJ, Bojanic S, Kerr RS. External ventricular drain infection: the effect of a strict protocol on infection rates and a review of the literature. *Br J Neurosurg*. 2006;20:296–300. doi: 10.1080/02688690600999901
392. Thamjamrassri T, Yuwapattanawong K, Chanthima P, Vavilala MS, Lele AV; EVDPop Study Collaborators. A narrative review of the published literature, hospital practices, and policies related to external ventricular drains in the United States: the External Ventricular Drain Publications, Practices, and Policies (EVDPop) study.

404. Al-Tamimi YZ, Bhargava D, Feltbower RG, Hall G, Goddard AJ, Quinn AC, Ross SA. Lumbar drainage of cerebrospinal fluid after aneurysmal subarachnoid hemorrhage: a prospective, randomized, controlled trial (LUMAS). *Stroke*. 2012;43:677–682. doi: 10.1161/STROKEAHA.111.625731
405. O'Connor KL, Westover MB, Phillips MT, Iftimia NA, Buckley DA, Ogilvy CS, Shafi MM, Rosenthal ES. High risk for seizures following subarachnoid hemorrhage regardless of referral bias. *Neurocrit Care*. 2014;21:476–482. doi: 10.1007/s12028-014-9974-y
406. Butzkueven H, Evans AH, Pitman A, Leopold C, Jolley DJ, Kaye AH, Kilpatrick CJ, Davis SM. Onset seizures independently predict poor outcome after subarachnoid hemorrhage. *Neurology*. 2000;55:1315–1320. doi: 10.1212/wnl.55.9.1315
407. Angriman F, Tirupakuzhi Vijayaraghavan BK, Dragoi L, Lopez Soto C, Chapman M, Scales DC. Antiepileptic drugs to prevent seizures after spontaneous intracerebral hemorrhage. *Stroke*. 2019;50:1095–1099. doi: 10.1161/STROKEAHA.118.024380
408. Marigold R, Gunther A, Tiwari D, Kwan J. Antiepileptic drugs for the primary and secondary prevention of seizures after subarachnoid haemorrhage. *Cochrane Database Syst Rev*. 2013;2013:CD008710. doi: 10.1002/14651858.CD008710.pub2
409. Panczykowski D, Pease M, Zhao Y, Weiner G, Ares W, Crago E, Jankowitz B, Ducruet AF. Prophylactic antiepileptics and seizure incidence following subarachnoid hemorrhage: a propensity score-matched analysis. *Stroke*. 2016;47:1754–1760. doi: 10.1161/STROKEAHA.116.013766
410. Chen Y, Xia F, Cai C, Li H, Ma L, Hu X, You C. Duration and choices of prophylactic anticonvulsants in subarachnoid hemorrhage: a systematic review and meta-analysis. *Neurosurg Rev*. 2021;44:2459–2467. doi: 10.1007/s10143-020-01466-1
411. Raper DM, Starke RM, Komotar RJ, Allan R, Connolly ES Jr. Seizures after aneurysmal subarachnoid hemorrhage: a systematic review of outcomes. *World Neurosurg*. 2013;79:682–690. doi: 10.1016/j.wneu.2012.08.006
412. Huttunen J, Kurki MI, von Und Zu Fraunberg M, Koivisto T, Ronkainen A, Rinne J, Jääskeläinen JE, Kälviäinen R, Immonen A. Epilepsy after aneurysmal subarachnoid hemorrhage: a population-based, long-term follow-up study. *Neurology*. 2015;84:2229–2237. doi: 10.1212/WNL.0000000000001643
413. Choi KS, Chun HJ, Yi HJ, Ko Y, Kim YS, Kim JM. Seizures and epilepsy following aneurysmal subarachnoid hemorrhage: incidence and risk factors. *J Korean Neurosurg Soc*. 2009;46:93–98. doi: 10.3340/jkns.2009.46.2.93
414. Naidech AM, Kreiter KT, Janjua N, Ostapkovich N, Parra A, Commichau C, Connolly ES, Mayer SA, Fitzsimmons BF. Phenytoin exposure is associated with functional and cognitive disability after subarachnoid hemorrhage. *Stroke*. 2005;36:583–587. doi: 10.1161/01.STR.0000141936.36596.1e
415. Szaflarski JP, Sangha KS, Lindsell CJ, Shutter LA. Prospective, random-penytoin efo suizures rophylacxs. . 20130;12:1652261762 doi:

-
443. Avert Trial Collaboration Group. Efficacy and safety of very early mobilisation within 24 h of stroke onset (AVERT): a randomised controlled trial. *Lancet*. 2015;386:46–55. doi: 10.1016/S0140-6736(15)60690-0
444. Klein AM, Howell K, Straube A, Pfefferkorn T, Bender A. Rehabilitation outcome of patients with severe and prolonged disorders of consciousness after aneurysmal subarachnoid hemorrhage (aSAH). *Clin Neurol Neurosurg*. 2013;115:2136–2141. doi: 10.1016/j.clineuro.2013.08.004
445. Olkowski BF, Binning MJ, Sanfillippo G, Arcaro ML, Slotnick LE, Veznedaroglu E, Liebman KM, Warren AE. Early mobilization in aneurysmal subarachnoid hemorrhage accelerates recovery and reduces length of stay. *J Acute Care Phys Ther*. 2015;6:47–55. doi: 10.1097/jat.0000000000000008
446. Gagnon DJ, Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, Eldridge A, Seder DB. Amantadine and modafinil as neurostimulants during post-stroke care: a systematic review. *Neurocrit Care*. 2020;33:283–297. doi: 10.1007/s12028-020-00977-5
447. Leclerc AM, Riker RR, Brown CS, May T, Nocella K, Cote J, Eldridge A, Seder DB, Gagnon DJ. Amantadine and modafinil as neurostimulants following acute stroke: a retrospective study of intensive care unit patients. *Neurocrit Care*. 2021;34:102–111. doi: 10.1007/s12028-020-00986-4
448. Kakehi S, Tompkins DM. A review of pharmacologic neurostimulant use during rehabilitation and recovery after brain injury. *Ann Pharmacother*. 2021;55:1254–1266. doi: 10.1177/1060028020983607
449. Fruehwald S, Gatterbauer E, Rehak P, Baumhackl U. Early fluoxetine treatment of post-stroke depression--a three-month double-blind placebo-controlled study with an open-label long-term follow up. *J Neurol*. 2003;250:347–351. doi: 10.1007/s00415-003-1014-3
- 450.